EMA/501661/2017

European Medicines Agency decision

P/0255/2017

of 4 September 2017

on the acceptance of a modification of an agreed paediatric investigation plan for grazoprevir / elbasvir (Zepatier), (EMEA-001604-PIP01-13-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0255/2017

of 4 September 2017

on the acceptance of a modification of an agreed paediatric investigation plan for grazoprevir / elbasvir (Zepatier), (EMEA-001604-PIP01-13-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0024/2015 issued on 30 January 2015, the decision P/0314/2015 issued on 21 December 2015 and the decision P/0025/2017 issued on 31 January 2017,

Having regard to the application submitted by Merck Sharp & Dohme (Europe), Inc. on 2 May 2017 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 21 July 2017, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for grazoprevir / elbasvir (Zepatier), film-coated tablet, granules, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Merck Sharp & Dohme (Europe), Inc., 5 Clos du Lynx / Lynx Binnenhof 5, B-1200 - Brussels, Belgium.

EMA/PDCO/305677/2017
London, 21 July 2017

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001604-PIP01-13-M03

Scope of the application

Active substance(s):

Grazoprevir / elbasvir

Invented name:

Zepatier

Condition(s):

Treatment of chronic hepatitis C

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Granules

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Merck Sharp & Dohme (Europe), Inc.

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme (Europe), Inc. submitted to the European Medicines Agency on 2 May 2017 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0024/2015 issued on 30 January 2015, the decision P/0314/2015 issued on 21 December 2015, and the decision P/0025/2017 issued on 31 January 2017.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 24 May 2017.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of chronic hepatitis C

The waiver applies to:

- the paediatric population from birth to less than 3 years of age;
- film-coated tablet, granules, oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of chronic hepatitis C

2.1.1. Indication(s) targeted by the PIP

Treatment of chronic hepatitis C infection in children and adolescents from 3 years to less than 18 years of age.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Granules

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1: Development of granules for oral use
Non-clinical studies	0	Not applicable.
Clinical studies	2	Study 2: Open-label, randomised, crossover, single-dose trial in healthy adults to evaluate relative bioavailability and safety of the age-appropriate oral solid dosage forms of grazoprevir and elbasvir versus the adult formulation.

		This study is the same as study 2 of the grazoprevir PIP EMEA-001602-PIP01-13 and subsequent modifications thereof and the elbasvir PIP EMEA-001603-PIP01-13 and subsequent modifications thereof Study 3: Open-label, single arm trial to evaluate pharmacokinetics, safety, antiviral activity and acceptability/palatability of grazoprevir in combination with elbasvir in children from 3 to less than 18 years of age with chronic hepatitis C genotype 1 and 4 infection. *This study is the same as study 2 of the grazoprevir PIP EMEA-001602-PIP01-13 and subsequent modifications thereof and the elbasvir PIP EMEA-001603-PIP01-13 and subsequent modifications thereof*
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2020
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of chronic hepatitis C

Authorised indication(s):

ZEPATIER is indicated for the treatment of chronic hepatitis C (CHC) in adults (see sections 4.2, 4.4 and 5.1).

For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1.

Authorised pharmaceutical form(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use